Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia

被引：3

作者：

Jacobson, Terry A. ^{[1
]}

机构：

[1] Emory Univ, Dept Med, Off Hlth Promot & Dis Prevent, Atlanta, GA 30345 USA

来源：

CLINICAL LIPIDOLOGY | 2014年 / 9卷 / 02期

关键词：

eicosapentaenoic acid; hypertriglyceridemia; icosapent ethyl; omega-3 fatty acid; statin; triglycerides; DENSITY-LIPOPROTEIN CHOLESTEROL; HIGH TRIGLYCERIDE LEVELS; CORONARY-ARTERY-DISEASE; FATTY-ACID FORMULATION; EPA LIPID INTERVENTION; ESTER TRANSFER PROTEIN; EICOSAPENTAENOIC ACID; CARDIOVASCULAR-DISEASE; HYPERCHOLESTEROLEMIC PATIENTS; DOCOSAHEXAENOIC ACID;

D O I：

10.2217/CLP.14.10

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Icosapent ethyl (IPE) is a prescription omega-3 fatty acid drug that significantly decreases triglycerides (TG) and has other beneficial lipid effects, including lowering non-high-density lipoprotein cholesterol and apolipoprotein B, without raising low-density lipoprotein cholesterol in patients with very high TG levels (MARINE trial) and in statin-treated patients with persistently high TG levels (ANCHOR trial). The safety and efficacy profile of IPE supports its use in patients with TG = 500 mg/dl and provides support for potential use in patients with high TG on statin therapy. A large ongoing outcomes trial (REDUCE-IT) will assess the efficacy of IPE in preventing cardiovascular events in high-risk, statin-treated patients with hypertriglyceridemia. As such, IPE may offer benefits over other dyslipidemia treatment options.

引用

页码：149 / 161

页数：13

共 50 条

[1] Overview of Prescription Omega-3 Fatty Acid Products for Hypertriglyceridemia
Weintraub, Howard S.
POSTGRADUATE MEDICINE, 2014, 126 (07) : 7 - 18
[2] Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)
Brinton, Eliot A.
Mason, R. Preston
LIPIDS IN HEALTH AND DISEASE, 2017, 16 : 1 - 13
[3] Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus
Tajuddin, Nadeem
Shaikh, Ali
Hassan, Amir
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2016, 9 : 109 - 118
[4] Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia
McKenney, James M.
Sica, Domenic
PHARMACOTHERAPY, 2007, 27 (05): : 715 - 728
[5] Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia
Skulas-Ray, Ann C.
West, Sheila G.
Davidson, Michael H.
Kris-Etherton, Penny M.
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (07) : 1237 - 1248
[6] Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia
Tatsuno, Ichiro
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (11) : 1261 - 1268
[7] A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study
Maki, Kevin C.
Bays, Harold E.
Ballantyne, Christie M.
Underberg, James A.
Kastelein, John J. P.
Johnson, Judith B.
Ferguson, James J.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (06):
[8] Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)
Braeckman, Rene A.
Manku, Mehar S.
Bays, Harold E.
Stirtan, William G.
Soni, Paresh N.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2013, 89 (04): : 195 - 201
[9] Prescription omega-3 carboxylic acids for the treatment of severe hypertriglyceridemia
Maki, Kevin C.
Poulos, Sylvia P.
Phillips, Alyssa K.
Lawless, Andrea L.
CLINICAL LIPIDOLOGY, 2014, 9 (04) : 399 - 406
[10] Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)
Eliot A. Brinton
R. Preston Mason
Lipids in Health and Disease, 16

← 1 2 3 4 5 →